Tianjin, 16 July 2025 - CanSino Biologics Inc. ("CanSinoBIO" or  "the Company") has announced that it has obtained clinical trial approval from the National Medical Products Administration (NMPA) of China to initiate relevant clinical trials for its Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (the "Recombinant Poliomyelitis Vaccine"). These trials will evaluate the vaccine's safety and immunogenicity against poliomyelitis caused by poliovirus types I, II, and III infections.

Polio is an acute viral infectious disease that can sometimes lead to a more serious and permanent paralysis. For those who become infected is incurable. Vaccination is the most effective way to prevent polio.

The Recombinant Poliomyelitis Vaccine is innovatively developed using structure-based protein design and virus-like particle (VLP) assembly, eliminating the need for live virus in production or testing. As a result, it offers enhanced safety and immune response potential. The World Health  Organization (WHO) recommends it as one of the leading strategies toward global polio eradication.

This vaccine is currently undergoing Phase I/II clinical trials in Indonesia to evaluate its safety and immunogenicity in infants and young children of specific ages. Furthermore, it can also be a component of a combination vaccine, which will be beneficial for wider promotion and thus eliminate poliomyelitis.